ALDEYRA THERAPEUTICS, INC. Total Long-Term Debt
ALDEYRA THERAPEUTICS, INC. (ALDX) had Total Long-Term Debt of $15.30 million as of 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-05-07
- 2026-03-31: Long-term Debt $15.30M.
- 2025-12-31: Long-term Debt $15.30M.
- 2025-09-30: Long-term Debt $15.30M.
- 2025-06-30: Long-term Debt $15.30M.
| Period end | Long-term Debt |
|---|---|
| 2026-03-31 | $15.30M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $15.30M 10-K · filed 2026-02-27 |
| 2025-09-30 | $15.30M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $15.30M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $15.30M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $15.30M 10-K · filed 2025-02-28 |
| 2024-09-30 | $15.59M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $15.29M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $15.29M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $15.29M 10-K · filed 2024-03-07 |
| 2022-12-31 | $16.34M 10-Q · filed 2023-11-03 |
| 2021-12-31 | $16.04M 10-Q · filed 2022-11-10 |
| 2020-12-31 | $16.04M 10-Q · filed 2021-10-28 |
| 2019-12-31 | $16.04M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $16.04M 10-Q · filed 2019-11-07 |
| 2017-12-31 | $1.40M 10-K · filed 2018-03-29 |
| 2016-12-31 | $1.40M 10-K · filed 2017-03-30 |
| 2015-12-31 | $1.40M 10-K · filed 2016-03-30 |
| 2014-12-31 | $1.40M 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |